{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:36:14Z","timestamp":1793910974261,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZZ1802"],"award-info":[{"award-number":["01ZZ1802"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZZ1802"],"award-info":[{"award-number":["01ZZ1802"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Advanced cholangiocarcinoma has a poor prognosis. Molecular targeted approaches have been proposed for patients after progression under first-line chemotherapy treatment. Here, molecular profiling of intrahepatic cholangiocarcinoma in combination with a comprehensive umbrella concept was applied in a real-world setting.<\/jats:p>\n                \n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In total, 101 patients received molecular profiling and matched treatment based on interdisciplinary tumour board decisions in a tertiary care setting. Parallel DNA and RNA sequencing of formalin-fixed paraffin-embedded tumour tissue was performed using large panels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Genetic alterations were detected in 77% of patients and included gene fusions in 21 patients. The latter recurrently involved the <jats:italic>FGFR2<\/jats:italic> and the <jats:italic>NRG1<\/jats:italic> gene loci. The most commonly altered genes were <jats:italic>BAP1<\/jats:italic>, <jats:italic>ARID1A<\/jats:italic>, <jats:italic>FGFR2<\/jats:italic>, <jats:italic>IDH1<\/jats:italic>, <jats:italic>CDKN2A<\/jats:italic>, <jats:italic>CDKN2B<\/jats:italic>, <jats:italic>PIK3CA<\/jats:italic>, <jats:italic>TP53<\/jats:italic>, <jats:italic>ATM<\/jats:italic>, <jats:italic>IDH2<\/jats:italic>, <jats:italic>BRAF<\/jats:italic>, <jats:italic>SMARCA4<\/jats:italic> and <jats:italic>FGFR3<\/jats:italic>. Molecular targets were detected in 59% of patients. Of these, 32% received targeted therapy. The most relevant reason for not initiating therapy was the deterioration of performance status. Patients receiving a molecular-matched therapy showed a significantly higher survival probability compared to patients receiving conventional chemotherapy only (HR: 2.059, 95% CI: 0.9817\u20134.320, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Molecular profiling can be successfully translated into clinical treatment of intrahepatic cholangiocarcinoma patients and is associated with prolonged survival of patients receiving a molecular-matched treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-022-01932-1","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T18:02:56Z","timestamp":1660932176000},"page":"1701-1708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Precision oncology for intrahepatic cholangiocarcinoma in clinical practice"],"prefix":"10.1038","volume":"127","author":[{"given":"Aurelie","family":"Tomczak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Springfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Dill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Hua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8187-3281","authenticated-orcid":false,"given":"Daniel","family":"Kazdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianeb","family":"Mehrabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antje","family":"Brockschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6288-8821","authenticated-orcid":false,"given":"Tom","family":"Luedde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Naumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albrecht","family":"Stenzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8888-1030","authenticated-orcid":false,"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"1932_CR1","unstructured":"Nakanuma Y, Curado MP, Franceschi S, Gores G, Paradis V, Sripa B, et al. Intrahepatic cholangiocarcinoma. In: Bosman FT, FC, Hruban RH, Theise ND, editors. WHO Classification of Tumours of the Digestive System. 4th edition. Lyon, France: International Agency for Research on Cancer (IARC); 2010. p. 217\u201324."},{"key":"1932_CR2","unstructured":"Klimstra DS, Lam AK, Paradis V, Schirmacher P. Tumours of the gallbladder and extrahepatic ducts. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. WHO classification of Tumours\u2014Digestive System Tumours. vol. 1. Lyon, France: WHO press; 2019. p. 265\u201394."},{"key":"1932_CR3","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1172\/JCI63212","volume":"122","author":"B Fan","year":"2012","unstructured":"Fan B, Malato Y, Calvisi DF, Naqvi S, Razumilava N, Ribback S, et al. Cholangiocarcinomas can originate from hepatocytes in mice. J Clin Invest. 2012;122:2911\u20135.","journal-title":"J Clin Invest"},{"key":"1932_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature13441","volume":"513","author":"SK Saha","year":"2014","unstructured":"Saha SK, Parachoniak CA, Ghanta KS, Fitamant J, Ross KN, Najem MS, et al. Mutant IDH inhibits HNF-4alpha to block hepatocyte differentiation and promote biliary cancer. Nature. 2014;513:110\u20134.","journal-title":"Nature."},{"key":"1932_CR5","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","volume":"18","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, et al. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18:2780\u201394.","journal-title":"Cell Rep."},{"key":"1932_CR6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/annonc\/mdt540","volume":"25","author":"JW Valle","year":"2014","unstructured":"Valle JW, Furuse J, Jitlal M, Beare S, Mizuno N, Wasan H, et al. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol. 2014;25:391\u20138.","journal-title":"Ann Oncol"},{"key":"1932_CR7","doi-asserted-by":"crossref","unstructured":"Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evidence. 2022;1:EVIDoa2200015.","DOI":"10.1056\/EVIDoa2200015"},{"key":"1932_CR8","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22:690\u2013701.","journal-title":"Lancet Oncol"},{"key":"1932_CR9","doi-asserted-by":"publisher","first-page":"3817","DOI":"10.1200\/JCO.2015.61.5997","volume":"33","author":"M Schwaederle","year":"2015","unstructured":"Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, et al. Impact of precision medicine in diverse cancers: a meta-analysis of phase II clinical trials. J Clin Oncol. 2015;33:3817\u201325.","journal-title":"J Clin Oncol"},{"key":"1932_CR10","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1001\/jamaoncol.2016.2129","volume":"2","author":"M Schwaederle","year":"2016","unstructured":"Schwaederle M, Zhao M, Lee JJ, Lazar V, Leyland-Jones B, Schilsky RL, et al. Association of biomarker-based treatment strategies with response rates and progression-free survival in refractory malignant neoplasms: a meta-analysis. JAMA Oncol. 2016;2:1452\u20139.","journal-title":"JAMA Oncol"},{"key":"1932_CR11","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S1470-2045(20)30157-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796\u2013807.","journal-title":"Lancet Oncol"},{"key":"1932_CR12","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669\u201377.","journal-title":"JAMA Oncol"},{"key":"1932_CR13","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"1932_CR14","first-page":"803","volume":"6","author":"M Javle","year":"2021","unstructured":"Javle M, Roychowdhury S, Kelley RK, Sadeghi S, Macarulla T, Weiss KH, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet. Gastroenterol Hepatol. 2021;6:803\u201315.","journal-title":"Gastroenterol Hepatol"},{"key":"1932_CR15","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","volume":"12","author":"F Meric-Bernstam","year":"2022","unstructured":"Meric-Bernstam F, Bahleda R, Hierro C, Sanson M, Bridgewater J, Arkenau HT, et al. Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study. Cancer Discov. 2022;12:402\u201315.","journal-title":"Cancer Discov"},{"key":"1932_CR16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejca.2017.10.013","volume":"87","author":"L Verlingue","year":"2017","unstructured":"Verlingue L, Malka D, Allorant A, Massard C, Ferte C, Lacroix L, et al. Precision medicine for patients with advanced biliary tract cancers: an effective strategy within the prospective MOSCATO-01 trial. Eur J Cancer. 2017;87:122\u201330.","journal-title":"Eur J Cancer"},{"key":"1932_CR17","unstructured":"Paradis V, Fukayama M, Park YN, Schirmacher P. Tumours of the liver and intrahepatic bile ducts. In: Lokuhetty D, White VA, Watanabe R, Cree IA, editors. WHO classification of Tumours\u2014Digestive System Tumours. vol. 1. Lyon, France: WHO press; 2019. p. 215\u201364."},{"key":"1932_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1136\/gutjnl-2018-317632","volume":"68","author":"T Longerich","year":"2019","unstructured":"Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, et al. RSPO2 gene rearrangement: a powerful driver of beta-catenin activation in liver tumours. Gut. 2019;68:1287\u201396.","journal-title":"Gut."},{"key":"1932_CR19","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/j.jtho.2019.07.006","volume":"14","author":"D Kazdal","year":"2019","unstructured":"Kazdal D, Endris V, Allgauer M, Kriegsmann M, Leichsenring J, Volckmar AL, et al. Spatial and temporal heterogeneity of panel-based tumor mutational burden in pulmonary adenocarcinoma: separating biology from technical artifacts. J Thorac Oncol. 2019;14:1935\u201347.","journal-title":"J Thorac Oncol"},{"key":"1932_CR20","doi-asserted-by":"crossref","unstructured":"Leichsenring J, Horak P, Kreutzfeldt S, Heining C, Christopoulos P, Volckmar AL, et al. Variant classification in precision oncology. Int J Cancer. 2019;145:2996\u20133010.","DOI":"10.1002\/ijc.32358"},{"key":"1932_CR21","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1172\/JCI130787","volume":"130","author":"MW Ronellenfitsch","year":"2020","unstructured":"Ronellenfitsch MW, Harter PN, Kirchner M, Heining C, Hutter B, Gieldon L, et al. Targetable ERBB2 mutations identified in neurofibroma\/schwannoma hybrid nerve sheath tumors. J Clin Investig. 2020;130:2488\u201395.","journal-title":"J Clin Investig"},{"key":"1932_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29:24\u20136.","journal-title":"Nat Biotechnol"},{"key":"1932_CR23","doi-asserted-by":"crossref","unstructured":"Kirchner M, Neumann O, Volckmar AL, Stogbauer F, Allgauer M, Kazdal D, et al. RNA-based detection of gene fusions in formalin-fixed and paraffin-embedded solid cancer samples. Cancers. 2019;11:1309.","DOI":"10.3390\/cancers11091309"},{"key":"1932_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-021-01100-3","volume":"23","author":"G King","year":"2021","unstructured":"King G, Javle M. FGFR inhibitors: clinical activity and development in the treatment of cholangiocarcinoma. Curr Oncol Rep. 2021;23:108.","journal-title":"Curr Oncol Rep."},{"key":"1932_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:405\u201324.","journal-title":"Genet Med"},{"key":"1932_CR26","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamaoncol.2019.0270","volume":"5","author":"RT Shroff","year":"2019","unstructured":"Shroff RT, Javle MM, Xiao L, Kaseb AO, Varadhachary GR, Wolff RA, et al. Gemcitabine, cisplatin, and nab-paclitaxel for the treatment of advanced biliary tract cancers: a phase 2 clinical trial. JAMA Oncol. 2019;5:824\u201330.","journal-title":"JAMA Oncol"},{"key":"1932_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/SLA.0000000000001850","volume":"264","author":"T Hackert","year":"2016","unstructured":"Hackert T, Sachsenmaier M, Hinz U, Schneider L, Michalski CW, Springfeld C, et al. Locally advanced pancreatic cancer: neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Ann Surg. 2016;264:457\u201363.","journal-title":"Ann Surg"},{"key":"1932_CR28","doi-asserted-by":"crossref","unstructured":"Phelip JM, Desrame J, Edeline J, Barbier E, Terrebonne E, Michel P, et al. Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study. J Clin Oncol. 2021;40:262\u201371.","DOI":"10.1200\/JCO.21.00679"},{"key":"1932_CR29","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N. Engl J Med. 2018;378:731\u20139.","journal-title":"N. Engl J Med"},{"key":"1932_CR30","doi-asserted-by":"crossref","unstructured":"Subbiah V, Lassen U, Elez E, Italiano A, Curigliano G, Javle M, et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21:1234\u201343.","DOI":"10.1016\/S1470-2045(20)30321-1"},{"key":"1932_CR31","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","volume":"7","author":"L Goyal","year":"2017","unstructured":"Goyal L, Saha SK, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7:252\u201363.","journal-title":"Cancer Discov"},{"key":"1932_CR32","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1158\/1535-7163.MCT-19-0631","volume":"19","author":"MA Krook","year":"2020","unstructured":"Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, et al. Efficacy of FGFR Inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Therapeut. 2020;19:847\u201357.","journal-title":"Mol Cancer Therapeut"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01932-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01932-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T23:13:15Z","timestamp":1666739595000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-022-01932-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,11,1]]}},"alternative-id":["1932"],"URL":"https:\/\/doi.org\/10.1038\/s41416-022-01932-1","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AT, DC, UW, AM, AB and PN declare no potential conflicts of interest that pertain to this work. CS reports honoraria for advisory boards from Roche, MSD, Bayer, Servier, AstraZeneca and Eisai outside the submitted work. MTD declares speaker and advisory board activities for AstraZeneca, Eisai and Roche outside the submitted work. DK declares personal fees from Agilent, AstraZeneca, Bristol-Myers Squibb, Lilly, Pfizer, and Takeda outside the submitted work. TLu declares research support and\/or speaker\u00b4s honoraria from AstraZeneca, Bayer, BMS, EASL, Incyte, MSD and Roche. AS declares speakers\u00b4 bureau and advisory board activities by AGCT, Aignostics, Amgen, AstraZeneca, Bayer, BMS, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Roche, Seattle Genetics, Takeda and Thermo Fisher as well as grant support by Bayer, BMS, Chugai, and Incyte. PS declares speakers\u00b4 bureau activities for BMS, Incyte, Eisai, Leica, Janssen, Novartis, advisory board activities for AstraZeneca, Bayer, BMS, Eisai, Incyte, MSD and Roche as well as grant support from BMS, Chugai, Incyte, MSD and Roche outside the submitted work. TLo declares the speaker\u00b4s honorarium by Incyte.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The LCCH registry study was approved by the local ethics committee of the Heidelberg University Hospital (S-693\/2019). Informed consent was obtained from all prospectively enrolled patients. The study was performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}